BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc. is a biotechnology company focused on developing and commercializing therapies for life-threatening rare diseases and medical conditions. Its approved products include VIMIZIM for mucopolysaccharidosis (MPS) IV type A, VOXZOGO for achondroplasia, NAGLAZYME for MPS VI, PALYNZIQ for phenylketonuria, BRINEURA for Batten disease, ALDURAZYME for MPS I, and KUVAN for phenylketonuria. The company also has pipeline candidates such as BMN 333 for growth disorders and BMN 351 for Duchenne muscular dystrophy.

BioMarin Pharmaceutical Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol BMRN. Its shares are traded in US dollars (USD), reflecting its primary listing in the United States. The company is headquartered in the United States and operates globally, serving customers including specialty pharmacies, hospitals, government agencies, distributors, and pharmaceutical wholesalers.

BioMarin Pharmaceutical Inc. operates in the Healthcare sector and is classified under the Biotechnology industry. As a biotechnology company, it focuses on developing treatments for rare genetic diseases using advanced biological approaches such as enzyme replacement therapy, recombinant proteins, and oligonucleotide therapies. Its products address lysosomal storage disorders, growth disorders, and metabolic conditions.

BioMarin's main approved products include VIMIZIM for MPS IV A, VOXZOGO for achondroplasia, NAGLAZYME for MPS VI, PALYNZIQ for phenylketonuria, BRINEURA for Batten disease, ALDURAZYME for MPS I, and KUVAN for phenylketonuria. These therapies are designed to treat life-threatening rare diseases. The company also has pipeline candidates such as BMN 333, a longer-acting CNP for growth disorders, and BMN 351, an oligonucleotide for Duchenne muscular dystrophy.

BioMarin generates revenue by selling its approved therapies to specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers globally. Its products are primarily enzyme replacement therapies and other biologics for rare diseases. The company also earns revenue from license agreements. Key revenue drivers include VIMIZIM, VOXZOGO, NAGLAZYME, PALYNZIQ, BRINEURA, ALDURAZYME, and KUVAN, which address various rare genetic disorders.